Skip to contentI
Inhibitor Therapeutics, Inc.
I
INTIInhibitor Therapeutics, Inc. Q4 2018 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$1.33M-$1.33MderivedN/M vs Q4 2017 EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$1,329,510N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inhibitor Therapeutics, Inc. · CIK 1042418 · Engraved from SEC EDGAR
Operating Cash Flowderived-$832,113N/M ended Dec 31, 2018 · filed Mar 7, 2019 · 66 d after period end